China's medical products administrator approved the clinical trial application of Jiangsu Hengrui Medicine (SHA:600276) units' HRS-6208 anti-tumor capsules, according to a Thursday filing.
Developed by Shanghai Hengrui Medicine and Shandong Shengdi Pharmaceutical, the capsules stop the phosphorylation activation or the addition of phosphates of cancer cells, helping prevent tumor cell proliferation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments